Aegis Capital Positive on Inovio Pharma (INO) as INO-3112 Phase 1/2a Starts

Aegis Capital affirms Inovio Pharma (AMEX: INO) at Hold with a price target of $10 folloiwng news that the company has commenced a Phase 1/2a trial to evaluate the safety, immunogenicity and clinical responses to its lead immunotherapy product, INO-3112, which consists of the firm's proprietary human papillomavirus (HPV)-targeted agent VGX-3100 plus its immune system activator expressing interleukin-12 (IL-12).

Analyst Ram Selvaraju comments on the trials design parameters, Subjects are slated to receive four administrations of INO-3112 every four weeks after completion of a standard chemotherapy / radiation regimen. Each INO-3112 dose is composed of a combination of 6mg of VGX-3100 and 1mg of DNA-based IL-12 delivered intramuscularly. As an exploratory analysis, clinical responses at the tumor site (tumor shrinkage or regression) and assess disease-free survival and disease recurrence up to 12 months after the initial immunotherapy with Inovio’s INO-3112 will be evaluated. T cell-based immune responses will be analyzed pre- and post-immunotherapy in the tumor tissue as well as in the bloodstream.

Selvaraju is poitive on this trail and expects data from the Phase 2 trial of VGX-3100 in high-grade cervical dysplasia within the coming weeks.

For an analyst ratings summary and ratings history on Inovio Pharmaceuticals click here. For more ratings news on Inovio Pharmaceuticals click here.

Inovio Pharmaceuticals closed at $9.21 yesterday.

You May Also Be Interested In

• Citi Upgrades Sirius XM Radio (SIRI) to Neutral, 'risk-reward is balanced at prevailing levels'
• KeyBanc Starts Super Micro Computer (SMCI) at Sector Weight, 'shares currently trading relatively inline with its infrastructure peer group'
• W.R. Berkley (WRB) PT Lowered to $85 at Evercore ISI